The Quantellect read.As of Nov 19, 2026, 11 active firms cover Celldex Therapeutics Inc: 10 rate it Buy or better, 1 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $34.00 to $100.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $64.82 sits 135% above the current $27.58. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.97 next quarter toward $-4.21 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 active firms
Buy
Strong Buy00%
Buy1091%
Neutral19%
Sell00%
Strong Sell00%
Based on 11 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$64.82
+135.0% upside
Average target across 11 active firms as of Nov 19, 2026 vs $27.58 current
Highest Target$100.00
Average Target$64.82
Lowest Target$34.00
Detailed analyst forecasts for CLDX
Showing 1–11 of 11 named analysts shown · 11 active firms in the rating projection
As of Nov 19, 2026, 10 of 11 active firms rate CLDX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CLDX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.97
Range $-1.14 – $-0.81 · 5 analysts · -18% YoY
Next period, 5 analysts expect Celldex Therapeutics Inc to earn $-0.97 a share (range $-1.14 – $-0.81), versus $-1.18 a year earlier. Full-year consensus is $-4.05, growing to $-4.21 the year after.
REVENUE · NEXT QUARTER
$250.0K
Range $0 – $1.0M · 5 analysts · +1567% YoY
Revenue is expected to reach $250.0K (range $0 – $1.0M), +1566.7% year-over-year. Full-year consensus is $1.4M, rising to $7.1M next year.
Top analysts covering Celldex Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLDX.
#1
Yatin Suneja
Guggenheim · Rank #84
Buy
$100.00+262.6% to target
Overall win rate
50%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #232
Buy
$72.00+161.1% to target
Overall win rate
38%
+ Follow
#3
EN
Edward Nash
Canaccord Genuity · Rank #270
Buy
$60.00+117.5% to target
Overall win rate
44%
+ Follow
#4
Joseph Pantginis
HC Wainwright & Co. · Rank #373
Buy
$64.00+132.1% to target
Overall win rate
34%
+ Follow
#5
Thomas Smith
Leerink Partners · Rank #412
Buy
$88.00+219.1% to target
Overall win rate
41%
+ Follow
CLDX stock forecast FAQ
What is CLDX's average 12-month price target?+
The 11 active firms with a live target average $64.82 for Celldex Therapeutics Inc over the next 12 months, ranging from a $100.00 high to a $34.00 low, as of Nov 19, 2026.
Is CLDX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 11 active firms as of Nov 19, 2026, 10 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CLDX?+
The Street-high target is $100.00 (Guggenheim), and the Street-low is $34.00 (Goldman Sachs). The average of all 11 active-firm targets is $64.82.
How many active Wall Street firms cover CLDX?+
11 active firms have a recognized rating on Celldex Therapeutics Inc as of Nov 19, 2026, and 11 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CLDX?+
Among analysts who currently cover CLDX, Yatin Suneja of Guggenheim has the strongest overall Quantellect track record (Rank #84). Their current call is Buy with a $100.00 target.
What is Celldex Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.97 per share (range $-1.14 – $-0.81) across 5 analysts. Full-year EPS is projected at $-4.05, rising to $-4.21 the following year.
How much revenue is Celldex Therapeutics Inc expected to report next quarter?+
Consensus revenue is $250.0K (range $0 – $1.0M). Full-year revenue is projected at $1.4M, growing to $7.1M next year.
Have analysts been upgrading or downgrading CLDX lately?+
As of Nov 19, 2026, 10 of 11 active firms rate CLDX a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.